REDWOOD CITY, CA (January 18, 2005) – Threshold Pharmaceuticals announced that Dr. Alan Colowick has been named Chief Medical Officer.
From 1999 to 2005, Colowick held a variety of positions with Amgen, most recently as vice president of European Medical Affairs, where he managed a regional, cross-functional medical affairs organization with responsibilities for all of Amgen’s therapeutic areas.
Prior to that, Colowick worked as senior director of Medical Affairs, leading the team through a Biologics License Application/Marketing Authorization Application and approval for Aranesp in the United States, European Union and Australia. He also had served at Amgen as director of product development and product development team leader in addition to overseeing the international clinical studies management.
Colowick received his M.D. from Stanford University School of Medicine and his M.P.H. from the Harvard School of Public Health. He completed his sub-specialty training in hematology and oncology at Brigham and Women’s Hospital and the Dana Farber Cancer Institute.
Threshold Pharmaceuticals is focused on the discovery, development, and commercialization of small molecule therapeutics based on “Metabolic Targeting.” This approach targets abnormal glucose metabolism – a fundamental property of most solid tumors and other diseases. The company’s initial focus is the treatment of cancer and benign prostatic hyperplasia, a disease characterized by overgrowth of the prostate.
